These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 27564097)

  • 1. Differential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy.
    Valdez BC; Li Y; Murray D; Brammer JE; Liu Y; Hosing C; Nieto Y; Champlin RE; Andersson BS
    Oncotarget; 2016 Sep; 7(39):63829-63838. PubMed ID: 27564097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of sodium butyrate on ABC transporters in lung cancer A549 and colorectal cancer HCT116 cells.
    Shi B; Xu FF; Xiang CP; Jia R; Yan CH; Ma SQ; Wang N; Wang AJ; Fan P
    Oncol Lett; 2020 Nov; 20(5):148. PubMed ID: 32934716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas.
    Lue JK; Prabhu SA; Liu Y; Gonzalez Y; Verma A; Mundi PS; Abshiru N; Camarillo JM; Mehta S; Chen EI; Qiao C; Nandakumar R; Cremers S; Kelleher NL; Elemento O; Amengual JE
    Clin Cancer Res; 2019 Sep; 25(17):5271-5283. PubMed ID: 30979734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HDAC inhibitors potentiate the apoptotic effect of enzastaurin in lymphoma cells.
    Bodo J; Sedlak J; Maciejewski JP; Almasan A; Hsi ED
    Apoptosis; 2011 Sep; 16(9):914-23. PubMed ID: 21667043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HDAC inhibitors downregulate MRP2 expression in multidrug resistant cancer cells: implication for chemosensitization.
    Kim H; Kim SN; Park YS; Kim NH; Han JW; Lee HY; Kim YK
    Int J Oncol; 2011 Mar; 38(3):807-12. PubMed ID: 21170509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells.
    Shimizu R; Kikuchi J; Wada T; Ozawa K; Kano Y; Furukawa Y
    Leukemia; 2010 Oct; 24(10):1760-8. PubMed ID: 20686505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumor activity of histone deacetylase inhibitors and the effect on ATP-binding cassette in ovarian carcinoma cells.
    Chao KC; Chang CC; Yen MS; Wang PH
    Eur J Gynaecol Oncol; 2010; 31(4):402-10. PubMed ID: 20882882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes.
    Hauswald S; Duque-Afonso J; Wagner MM; Schertl FM; Lübbert M; Peschel C; Keller U; Licht T
    Clin Cancer Res; 2009 Jun; 15(11):3705-15. PubMed ID: 19458058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer.
    Björkman M; Iljin K; Halonen P; Sara H; Kaivanto E; Nees M; Kallioniemi OP
    Int J Cancer; 2008 Dec; 123(12):2774-81. PubMed ID: 18798265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suberoylanilide hydroxamic acid (SAHA) and cladribine synergistically induce apoptosis in NK-LGL leukaemia.
    Sun X; Hasanali ZS; Chen A; Zhang D; Liu X; Wang HG; Feith DJ; Loughran TP; Xu K
    Br J Haematol; 2015 Feb; 168(3):371-83. PubMed ID: 25284154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of histone deacetylase inhibitors on ATP-binding cassette transporters in lung cancer A549 and colorectal cancer HCT116 cells.
    Wang H; Chi CH; Zhang Y; Shi B; Jia R; Wang BJ
    Oncol Lett; 2019 Jul; 18(1):63-71. PubMed ID: 31289473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176).
    Robey RW; Zhan Z; Piekarz RL; Kayastha GL; Fojo T; Bates SE
    Clin Cancer Res; 2006 Mar; 12(5):1547-55. PubMed ID: 16533780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities.
    Dedes KJ; Dedes I; Imesch P; von Bueren AO; Fink D; Fedier A
    Anticancer Drugs; 2009 Jun; 20(5):321-33. PubMed ID: 19322073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat.
    To KK; Tong WS; Fu LW
    Lung Cancer; 2017 Jan; 103():58-65. PubMed ID: 28024697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma.
    Jimura N; Fujii K; Qiao Z; Tsuchiya R; Yoshimatsu Y; Kondo T; Kanekura T
    J Dermatol Sci; 2021 Mar; 101(3):194-201. PubMed ID: 33531202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of class I histone deacetylase inhibitor romidepsin in combination regimens.
    Petrich A; Nabhan C
    Leuk Lymphoma; 2016 Aug; 57(8):1755-65. PubMed ID: 27118119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma.
    Venturelli S; Armeanu S; Pathil A; Hsieh CJ; Weiss TS; Vonthein R; Wehrmann M; Gregor M; Lauer UM; Bitzer M
    Cancer; 2007 May; 109(10):2132-41. PubMed ID: 17407132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased MDR1 Transporter Expression in Human Brain Endothelial Cells Through Enhanced Histone Acetylation and Activation of Aryl Hydrocarbon Receptor Signaling.
    You D; Wen X; Gorczyca L; Morris A; Richardson JR; Aleksunes LM
    Mol Neurobiol; 2019 Oct; 56(10):6986-7002. PubMed ID: 30963442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.